UCART20x22 + CLLS52
Phase 1/2Recruiting 1 views this week 0 watching💤 Quiet
Interest: 29/100
29
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
B-cell Non-Hodgkin Lymphoma (B-NHL)
Conditions
B-cell Non-Hodgkin Lymphoma (B-NHL)
Trial Timeline
Nov 1, 2022 → Aug 1, 2027
NCT ID
NCT05607420About UCART20x22 + CLLS52
UCART20x22 + CLLS52 is a phase 1/2 stage product being developed by Cellectis for B-cell Non-Hodgkin Lymphoma (B-NHL). The current trial status is recruiting. This product is registered under clinical trial identifier NCT05607420. Target conditions include B-cell Non-Hodgkin Lymphoma (B-NHL).
What happened to similar drugs?
3 of 20 similar drugs in B-cell Non-Hodgkin Lymphoma (B-NHL) were approved
Approved (3) Terminated (2) Active (15)
Hype Score Breakdown
Clinical
9
Activity
15
Company
5
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT05607420 | Phase 1/2 | Recruiting |
Competing Products
20 competing products in B-cell Non-Hodgkin Lymphoma (B-NHL)